Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180.
BEC, a standard mixture of solasodine glycosides is effective in vivo against murine sarcoma 180 (S180), whereas the aglycone solasodine at equimolar concentrations is ineffective. The efficacy of BEC against S180 in vivo can be inhibited by rhamnose. Mice which are in their terminal stage with S180 can tolerate and become symptom-free of cancer by single dose administration of BEC at concentrations of BEC three times the LD100 for normal mice. These observations suggest that the binding of solasodine glycosides on tumour cells may be mediated through the monosaccharide rhamnose, which forms part of solasonine, solamargine and di-glycosides of solasodine in BEC. Furthermore, these results provide evidence that BEC selectively destroys tumour cells relative to normal cells in vivo.
Cham
B E
BE
University of Queensland, Department of Medicine, Australia.
Daunter
B
B
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D006027:Glycosides / Q000494:pharmacology* / Q000633:toxicity; D051379:Mice; D009368:Neoplasm Transplantation; D012210:Rhamnose / Q000494:pharmacology; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D012991:Solanaceous Alkaloids / Q000494:pharmacology* / Q000633:toxicity
D006027:Glycosides; D012991:Solanaceous Alkaloids; C012037:solasodine; D012210:Rhamnose